Scholar Rock, Inc.
Clinical trials sponsored by Scholar Rock, Inc., explained in plain language.
A biopharmaceutical company developing therapies targeting growth factors for neuromuscular and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a muscle-boosting antibody help people with spinal muscular atrophy over the long haul? Results expected Nov 2026 (estimated) May already have reported ↗
- New drug SRK-439 tested for safety in healthy adults Results expected Dec 2026 (estimated)
-
Can a Muscle-Saving drug boost weight loss?
Disease control CompletedThis phase 2 study tested whether adding apitegromab (a drug that blocks a muscle-weakening protein) to tirzepatide (a GLP-1 weight-loss drug) helps overweight and obese adults lose fat while keeping lean muscle. 102 participants received either the combination or placebo over 24…
Phase 2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New Muscle-Boosting drug shows promise for SMA patients in major trial
Disease control CompletedThis Phase 3 trial tested apitegromab, a drug that blocks a muscle-limiting protein, in 188 nonambulatory children and young adults with later-onset spinal muscular atrophy (SMA types 2 and 3). All participants were already taking standard SMA therapies (nusinersen or risdiplam).…
Phase 3 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC